Overview
- Lilly’s market value sits near $900 billion and the shares trade at more than 40 times trailing earnings, with the stock down about 8% this year even as consensus targets suggest roughly 24% upside to around $1,230.
- Q4 2025 revenue reached $19.3 billion and full-year sales were $65.2 billion, reflecting exceptional growth alongside strong profitability.
- Sales were driven by tirzepatide volume: Mounjaro generated $7.4 billion in Q4 and $23.0 billion for 2025, and Zepbound delivered $4.3 billion in Q4 and $13.5 billion in its first full year as pricing pressure modestly offset expanding access.
- Management guided 2026 revenue to $80–$83 billion with non‑GAAP EPS up to $35, indicating expectations for continued demand.
- The company is investing heavily in oral GLP‑1 and triple‑agonist candidates such as orforglipron and retatrutide and building multi‑billion‑dollar manufacturing capacity in the U.S. and Europe to support long‑term growth.